Shretta, R., Coghlan, R., Erps, J.van, Renshaw, M.
This report was commissioned by MMV and the RBM Partnership’s Procurement and Supply Chain Management working group in recognition of the Abuja targets and WHO recommendation for confirming diagnosis of malaria prior to treatment. It brings together documented data from 45 African malaria-endemic countries, up to October 2009, on the status of funding and estimated commodity needs in order to assure increased coverage of malaria diagnostics and treatment. The key findings of the report include: the definition of 'need' may require refinement; there is a need for a common definition of ‘universal coverage’ for artemisinin-based combination therapy (ACT) and rapid diagnostic test (RDT) scale-up; although there has been a significant scale up in both ACTs and RDTs in recent years, there is a need to address the current imbalance between ACT and RDT procurements (ACT estimates are currently significantly higher than RDT estimates), in order to align with current WHO guidance on confirmed diagnosis before treatment; improved understanding of expected consumption is needed; availability of funding is a dynamic process; improved monitoring of need, funding and consumption data is needed; comparison of quantification methodologies would be useful; and all data should be regularly verified at country level when used for programmatic purposes.
Report carried out on behalf of the Roll Back Malaria (RBM) Procurement and Supply Chain Working Group (PSMWG) and Medicines for Malaria Venture (MMV), 2009; 53 pp.